In 2020, FLAURA Phase III study comprehensively evaluates clinical benefits between osimertinib and first generation TKIs for untreated advanced-stage NSCLC with EGFR sensitive mutations. The gene discussed is EGFR; the disease is non-small cell lung carcinoma.